Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib +/- Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
NCT02468557Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idelalisib in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events, Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities and 1 more. Started Jul 2015; status: terminated.
02
Drugs
idelalisib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02468557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468557.